BriaCell Therapeutics Corp. (BCTXW)

0.3999 +0.0299 (+8.08%) At close: 04:00PM EDT

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 -15th Street
West Vancouver, BC V7T 2X1
Canada
604 921 1810
https://briacell.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 16

Key executives

Name	Title	Pay	Exercised	Year born
Dr. William V. Williams M.D.	CEO, President & Director	785.3k	N/A	1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.	CFO & Corporate Secretary	304.46k	N/A	1973
Dr. Miguel A. Lopez-Lago Ph.D.	Chief Scientific Officer	298.9k	N/A	1969
Dr. Giuseppe Del Priore M.D., M.P.H., MPH	Chief Medical Officer	492.5k	N/A	1962
Dr. Charles Louis Wiseman FACP, M.D.	Founder, Principal Research Advisor & Member of Scientific Advisory Board	241.14k	N/A	1946

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Corporate governance

BriaCell Therapeutics Corp.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.